Eisai seeks marketing authorisation for lenvatinib from EMA

Eisai has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for first-line use of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news